If you are talking about the pre-publication meta analysis, it merely bundles a bunch of extremely small studies, of different doasages, looking for differing outcomes, in differing trials, under differing conditions and tries to make some broad claims. Worse, many of those studies involved combined therapies, which can make no claims about the effectiveness of Ivermectin directly.
It is a falacy to believe that one can select a large number of individually unreliable studies and derive reliable data from it. You **may** come to the correct solution. Or not.
Personally, I'm not rejecting Ivermectin treatment out of hand, but reliable clinical evidence as to its effectiveness against COVID-19 is somewhere between scant and lacking. Even CS KOW, who did an early meta-analysis suggesting it was worth exploring (back in Feb/Mar) has subsequently printed a new paper indicating the past data was unreliable.
There have been a number of very public retractions as well, including (perhaps most famously at present) the Elgazzar study which accounted for a large portion of the beneficial effect reported in later meta-studies. Indead, Chaccour (whose TINY and statistically irrelevant study is cited approvingly below) is interviewed in the link provided, and he doesn't support Ivermectin use, only more investigation.
The Lopez-Medina study is also cited approvingly in this meta-analysis, but its been flagged as problematic as well.
The numbers don't add up. Nor were its protocols followed - including mixing dosages of ivermectin and the placebo. A large number of the other studies here are retrospective, greatly increasing the chances of cherry picking a subset of data.
View attachment 2821214